Member Info for originalharrystamper

The following link is a really detailed and interesting read of "The Application of Aptamer and Research Progress in Liver Disease":

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087326/

Absolutely meant HAVEN'T even bothered on previous post!!!! Jeez, what a time to not check through before posting!

As a past investor in ZED I would have ploughed money into this stock when I came across information and articles in the public domain before being RNS'd or put out by their own media outlet. Today, I have even bothered after reading this latest article. My trust tank is completely empty

Why haven't ZED RNS'd the following media post?

https://www.maritimeaviation.com/post/the-world-of-firefighting-has-changed

Says it was posted 2 days ago and also posts and links are on LinkedIn. I would have thought it might help shore up the current SP perhaps. Or then again, will it just have an affect similar to the previous distributor RNS?

Hi LT, thanks for the links. I guess we’ll find out when the name is finally released in an RNS update or other media outlet. For now, I will look upon this from a positive angle and assume that whilst I agree with the statement in your first link - that references ‘historical partnerships’ with 15 of the 20 top Pharmas from 2020, this doesn’t necessarily mean that they were referencing the same when stated top 15 in the April RNS. This could well be the current top 15 as it doesn’t state 2020 (nor does it state 2023/24 either). I’ll ask you this though; why did they say ‘top 15’ and not top 10? Top 5, top 8 etc….. why not just say top 20 and keep it vague?

So, if I am correct in thinking - Boehringer Ingleheim, whilst trialling Zealand Pharma's Survodutide (under development for the treatment of non-alcoholic steatohepatitis (NASH), liver fibrosis, type 2 diabetes and obesity) they found during sub-analysis that up to 64.5% of adults with fibrosis stages F2 and F3 (moderate to advanced scarring) achieved an improvement in fibrosis without worsening of MASH (Metabolic dysfunction-associated steatohepatitis - inflammation of the liver caused by excess fat cells in it). Could Aptamer Group's Optimer now be used to specifically target fibrosis??, as mentioned in the April RNS "it's Optimer binder against cells associated with fibrotic liver disease, developed for targeted delivery of therapeutic payloads to fibrotic liver disease, has been shipped to a top 15 pharmaceutical company for evaluation in their own therapeutic applications".

I'm very keen to read other views here - like I said, I'm new here and I'm sure there's a substantial amount of informative investors on here already. I just kept circling back to Boehringer regarding liver disease and fibrosis, like this next link (interestingly also released on 22/04/24):

https://www.biospace.com/article/boehringer-teams-with-ochre-bio-in-potential-1b-deal-to-develop-regenerative-liver-drugs/

First time post here but I've been background reading and researching the past week. That might not sound long enough but I've mainly been concentrating on trying to identify the name of the company in the 22/04/24 RNS https://www.lse.co.uk/rns/APTA/top-pharma-company-evaluates-optimer-for-medicine-rz9mgyaw7jo32d4.html

Could it be Boehringer Ingelheim???

Below article released today:

https://www.boehringer-ingelheim.com/us/results-phase-ii-mash-trial-announced-easl-2024

......and also, coming in at No.14 in the charts:

https://www.fiercepharma.com/pharma/top-20-pharma-companies-2023-revenue

How insightful Traxpern. Hold my beer whilst I log in to my account and buy some stock on your solid statement of ZED flying past 2p today. Pfffft. They IPO'd and came to market at 19p per share placing price, have losses totalling nearly £5m!(£1.15 up to Nov 2021, £2m Nov 2022 and £1.7m Nov 2023) and todays SP is now just over 8% of its 19p placing price @ 1.6p!! I'd like to see to have a read of their actual R&D breakdown costs. It seems that this phrase is all too easily used to justify losses in all too many company statements that I read

Shocker

BigDom - Read the RNS

Link didn't seem to work so trying again:

https://find-and-update.company-information.service.gov.uk/company/10804894/officers

Furthermore, we are to believe that DRIPS AND SPARKS (no accounts posted since 31/03/2022), an Electrical Installation Business (is it this same company? https://www.checkatrade.com/trades/dripsandsparksltd) has placed a 200,000 litre paint order worth £2.4m over 2 years, for steel surfaces at Gracewood Construction Ltd's project sites in the UK, with deliveries commencing immediately?? Can anyone, anyone at all, add a link here so I can read anything about the 'Sprayers Group' Drips and Sparks and what their experience is? Any past/current projects?

A deeper dive of research often finds some interesting bits 'n' bobs:

When you look up Zensafe on Companies House, you will see it has one Officer noted as ABEL, Nathan Davis, with a DOB of Sept 1988. If you click on his name it will come up with 17 other companies he is/has been associated with. This is not the interesting part. If you search a little more, you will see that the same name Nathan Davis ABEL (DOB Sept 1988) is also listed as an Officer for DIGITAL MINE LIMITED (https://find-and-update.company-information.service.gov.uk/company/10804894/officers) but this company is not listed as one of the 17, it is listed with one other ACXTIVE Director......Francois Daniel CHKLAR (DOB: Oct 1979). Francois CHKLAR (DOD: Oct 1979) if you recall from the £2.4m paint order is the named Director of DRIPS AND SPARKS LIMITED (https://find-and-update.company-information.service.gov.uk/company/10093759/officers). Why were these 2 named persons so difficult to link when they now obviously know each other, having both been Directors of the same company DIGITAL MINE???

And another one.......it's like I know what I'm talking about. Who'd have thought it

250,000 sell @ 14:49

And then I expect to see a new 52 week low in SP. Expect to see more sells today in the 100- 250k range as an indicator of the potential results to come imo

Nope. Try again

And there you have it - selling price now at the same level as before the latest RNS regarding the NHS. The market can't be fooled, no matter how you word a RNS.......and some of us are also pretty good at using the internet to dig a bit deeper into those words

No probs llejb. I bet if anyone who holds here tries to sell some stock of £1k or more (probably even less), they can’t get a live price. I’d be interested to know